Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
33.03
+0.89 (2.77%)
Aug 19, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Stoke Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $47. The average 1-year stock price forecast is 42.29% higher than the current stock price, while the lowest is $35 (+5.96%) and the highest is $60 (+81.65%).
Price Target: $47 (+42.29%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Stoke Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 11 | 11 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $58 | Buy | Reiterates | $58 | +75.60% | Aug 13, 2026 |
| Wolfe Research | Wolfe Research | Buy Maintains $40 | Buy | Maintains | $40 | +21.10% | Aug 4, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Maintains $50 | Buy | Maintains | $50 | +51.38% | Aug 4, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $44 | Buy | Maintains | $44 | +33.21% | Aug 4, 2026 |
| TD Cowen | TD Cowen | Buy Reiterates $60 | Buy | Reiterates | $60 | +81.65% | Aug 4, 2026 |
Financial Forecast
Revenue This Year
30.98M
from 184.42M
Decreased by -83.20%
Revenue Next Year
40.87M
from 30.98M
Increased by 31.92%
EPS This Year
-3.62
from -0.12
EPS Next Year
-3.49
from -3.62
EPS and Forward PE are based on non-GAAP adjusted numbers.